Since prostate cancer incidence data are available only through 2012, additional surveillance data are needed to determine the long‐term impact of declining PSA screening on prostate cancer diagnosis and mortality, particularly with regard to the incidence rate of stage IV cancers. This evidence concerns the gene KLK3 and prostate carcinoma.